Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company, has ignited anticipation within the medical community by unveiling its plans to showcase groundbreaking research at the upcoming Society for Immunotherapy of Cancer (SITC) event in Houston, Texas, slated for November 6-10, 2024.

Discovering Innovations:

Poster Previews: Novelties such as a novel anti-GPC3 CAR-M for hepatocellular carcinoma and the Phase 1 study of autologous monocytes engineered for participants with HER2 overexpressing solid tumors will be unveiled during this prestigious medical gathering.

Insightful Sessions: Attendees can look forward to the sessions scheduled for Friday, November 8, 2024, at Exhibit Halls A B George R. Brown Convention Center.

Virtual Gallery: The posters presented at this event will be available online on Carisma’s website post the commencement of the poster session.

About Carisma Therapeutics: The Company’s pioneering work in utilizing macrophage and monocyte cell engineering to develop transformative immunotherapies has positioned them as a prominent player in the fight against cancer and other severe diseases.

Forward-Thinking Outlook: Carisma’s dedication to advancing product candidates and enhancing their clinical development signals a promising future in the field of biopharmaceuticals.

Staying Vigilant: Potential risks and uncertainties associated with forward-looking statements are acknowledged, with a commitment to navigate them with prudence and acumen.

Engagement: Investors and media contacts can reach out to the respective personnel for inquiries, maintaining a steady dialogue between Carisma Therapeutics and its stakeholders for shared progress.

View original content to download multimedia:

Carisma Therapeutics Announcement

SOURCE Carisma Therapeutics Inc.